Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of twice-daily oral buspirone on core
features of autism in autistic children aged 2-6 years as measured by the change from
baseline in the Autism Diagnostic Observation Schedule (ADOS) Composite Total scores compared
to placebo at 6 months.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Chugani, Diane C.
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)